ReviewCurrent obesity reports2026
Unraveling the Potential Role of Spexin in Exercise-Induced Improvement of Cardiometabolic Health in Obesity and Diabetes.
Review in Current obesity reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purpose of reviewThis review aims to summarize current knowledge of the intrinsic relationship between exercise, spexin, and cardiovascular diseases associated with obesity and diabetes and provide mechanistic insights into the beneficial effect of exercise on obesity, diabetes and cardiovascular diseases. RECENT
findingsEmerging evidence indicates that spexin has been shown to be beneficial for diabetes and cardiometabolic health in preclinical models. In obese or diabetic states, circulating levels of spexin are significantly reduced, leading to skeletal muscle, the liver, and cardiac muscle becoming more susceptible to insulin resistance. Conversely, exercise triggers the release of spexin under obese or diabetic states, which may improve insulin resistance and cardiometabolic disorders. The mechanisms underlying the improvement of insulin resistance and cardiovascular disorders due to spexin involve increasing glucose uptake, fatty acid oxidation, and mitochondrial biogenesis, as well as reducing the mitochondrial oxidative stress in cardiac tissues. This review summarizes our recent studies and those of others to highlight the underlying molecular mechanisms of the effects of exercise induced spexin on diabetes and cardiovascular diseases. These insights shed new light on the pathophysiology of diabetes and cardiovascular disease based on preclinical studies and may provide useful clues for developing a combination of spexin and exercise as an effective therapeutic strategy for preventing or treating cardiometabolic disorders of obesity and diabetes.
Indexed as
Identifiers
41862764What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.